Kevin Conway's departure as Chief Financial Officer of Generation Bio Co. was reported; the filing names no successor. As of November 15, 2026, Generation Bio Co. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 9, 2026, naming 1 departure (Form 8-K, February 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Generation Bio Co? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Generation Bio Co. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-09. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Generation Bio Co. files it.
Also on the record for Generation Bio Co.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G/A, by Atlas Venture Fund X, L.P. | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 3.1% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 4.27% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Baselake Partners, LP | — | 5%+ stakes | Source |
| February 9, 2026 | Acquired by XOMA Royalty Corporation | — | Acquisition | Source |
| February 6, 2026 | Stake report, Schedule 13G, by Baselake Partners, LP | 5.2% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by SymBiosis Capital Partners, LLC | 6.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by SymBiosis Capital Partners, LLC | 6.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 8.6% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Renaissance Technologies LLC | 5.11% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 12.6% of the class | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 3.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Generation Bio Co. now and the warning signs.
Free to see. No signup.
Keep reading
More on Generation Bio Co. and the records around it.
Generation Bio Co. elsewhere on the record
- 5%+ stake filings May 2026
- Acquisition Apr 2026
Companies that share a holder
- SymBiosis Capital Partners, LLC also filed stake reports on 1 other company: Rani Therapeutics Holdings, Inc. (May 2026)
- Atlas Venture Fund X, L.P. also filed stake reports on 5 other companies: Kymera Therapeutics, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), Q32 Bio Inc. (May 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Athira Pharma, Inc. (Feb 2026)
Watch Generation Bio Co.
Get an email when Generation Bio Co. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Generation Bio Co.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Generation Bio Co.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Generation Bio Co. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-09 | Out | Chief Financial Officer | 8-K, 2026-02-09 |
Why did they leave? What the filings say
Generation Bio Co.'s filings state no reason for the departures below. Where a filing gives none, it says so here; nothing is inferred.
- Kevin Conway, Chief Financial Officer (filed 2026-02-09): the filing states no reason.
Who leads Generation Bio Co., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Kevin Conway, departure reported (filed 2026-02-09). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Generation Bio Co.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Generation Bio Co., with the record behind each one.
Find candidates like Chief Financial Officer at Generation Bio Co.Every change, in the filing's words
Departing: Kevin Conway, Chief Financial Officer
Also in accordance with the terms of the Merger Agreement, each incumbent officer of the Company as of immediately prior to the Effective Time, including Yalonda Howze, JD, the Company's Interim Chief Executive Officer and President, and Kevin Conway, the Company's Chief Financial Officer, ceased to serve as an officer of the Company and terminated employment with the Company, effective as of the Effective Time.
- The foregoing resignations were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies or practices.
- In accordance with the terms of the Merger Agreement, each officer of Merger Sub immediately prior to the Effective Time became an officer of the Surviving Corporation, effective as of the Effective Time.
- The sole officer of Merger Sub immediately prior to the Effective Time was Owen Hughes, its President, Treasurer, and Secretary.
Tools for this story
Each opens in a new tab, filled in for Generation Bio Co.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
